6-7 NEWS
Lilly to acquire Merida for $2.875bn; J&J to pay $5.5bn to end talc litigation

8-9 NEWS
Pfizer/Valneva’s Lyme disease vaccine; LEO Pharma acquires rights from Tanabe Pharma

10 DERMATOLOGY NEWS
AbbVie’s Rinvoq approved for vitiligo; MSD/Moderna's potential vaccine for melanoma

12 DARWIN’S MEDICINE
Are you over-imitating with SWOT analysis?

13 THE HEAT IS ON
The impact of climate change on sustainability

14 HEART AND HUMANITY
Healthcare comms compete with technology

15 TRANSLATING STRONG DATA
Teams need to show the clearest therapy value

16-18 REALISING THE TRUE VALUE OF HEALTH
Amy Grey and Nina Pinwill from J&J talk about why industry needs to engage earlier, explain value more clearly, understand service pressures and take shared responsibility for implementation

20-21 CELL AND GENE THERAPIES - MOVING TOWARDS BROADER CLINICAL
Professor Jacob George, Chief Medical and Scientific Officer at the MHRA, looks at the regulatory challenges of cell and gene therapies for serious or life-threatening rare diseases

22-23 WHY PHARMA NEEDS HUMANS AT THE HELM OF AI
The Communiqué Awards, with 32 categories, showcases the work shaping the industry. This year, new awards were introduced, including Healthcare Communications Writer of the Year

28-29 STRENGTHENING ENGAGEMENT WITH HCPS
Closing the critical gap between HCPs’ need for information and the pharma industry’s ability to deliver relevant, tailored content – using AI to make engagement more precise, rather than just creating more of it

30-32 THE IMPACT OF AI ON CHRONIC DISEASES
Over the past decades, advances in information technology have fundamentally transformed the management of chronic diseases, but what impact is this having on the pharma industry?

34-35 ADAPTING TO REGULATORY UNCERTAINTY
As global regulatory expectations continue to evolve and diverge across regions, often at unpredictable speed, pharma companies are rethinking how they resource and operate, making functional service provider models a strategic path forward

September 2026